Search results for " vascular endothelial growth factor"

showing 10 items of 54 documents

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

2017

Abstract: Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis process and their expression on tumor samples has been explored as prognostic marker in both cholangiocarcinoma and gallbladder cancer. Recent studies evaluated the genomic landscape of BTCs and…

0301 basic medicineMAPK/ERK pathwayVascular Endothelial Growth Factor AAngiogenesisDrug Evaluation PreclinicalTyrosine kinase inhibitorAngiogenesis InhibitorsReviewFibroblast growth factorCatalysiMetastasisAntineoplastic Agentlcsh:Chemistrychemistry.chemical_compoundangiogenesis0302 clinical medicinetyrosine kinase inhibitorsMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyClinical Trials as TopicMonoclonal antibodieNeovascularization Pathologicvascular endothelial growth factorComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorGene Expression Regulation NeoplasticAngiogenesiChemistryBiliary Tract NeoplasmsTreatment OutcomeBiliary Tract Neoplasm030220 oncology & carcinogenesismonoclonal antibodiesTyrosine kinaseAngiogenesis InhibitorHumanSignal TransductionProtein Kinase InhibitorAntineoplastic Agentsbiliary tract cancersBiologyModels BiologicalAngiogenesis; Biliary tract cancers; Monoclonal antibodies; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Drug Evaluation Preclinical; Gene Expression Regulation Neoplastic; Genetic Variation; Humans; Models Biological; Neovascularization Pathologic; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A; Molecular Targeted Therapy; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryCatalysisInorganic Chemistry03 medical and health sciencesIn vivomedicineAnimalsHumansPhysical and Theoretical ChemistryGallbladder cancerMolecular BiologyProtein Kinase InhibitorsBiologyAnimalOrganic ChemistryGenetic Variationmedicine.disease030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Immunologyangiogenesis; biliary tract cancers; monoclonal antibodies; tyrosine kinase inhibitors; vascular endothelial growth factorCancer researchBiliary tract cancerInternational Journal of Molecular Sciences
researchProduct

Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung can…

2020

The introduction of licensed front-line immunotherapies has heralded a new era for the treatment of non-oncogene-addicted, advanced non-small cell lung cancer (NSCLC). Yet as with all evolutions in clinical management, changes in practice can outpace the availability of the clinical evidence needed to inform subsequent therapeutic decision making. At the time of writing, there is limited available evidence on the optimum therapeutic options after progression on immunotherapy. Further research is needed to define mechanisms of immunotherapy resistance in patients with advanced NSCLC, and to understand the implications for subsequent treatment response. Pending the availability of robust clin…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentNintedanibContext (language use)Angiogenesis InhibitorsAnti-angiogenic drugNon-oncogene-addicted non-small cell lung cancer (NSCLC)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineTumor MicroenvironmentHumansTumor microenvironment (TME)Lung cancerImmune Checkpoint InhibitorsTumor microenvironmentAnti-angiogenic drug; Immunotherapy resistance; Nintedanib; Non-oncogene-addicted non-small cell lung cancer (NSCLC); Tumor microenvironment (TME); Vascular endothelial growth factor (VEGF)Oncogenebusiness.industryVascular endothelial growth factor (VEGF)ImmunosuppressionImmunotherapymedicine.diseaseImmunotherapy resistance030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisNintedanibNon small cellImmunotherapybusiness
researchProduct

Oxidative stress in retinal pigment epithelium cells increases exosome secretion and promotes angiogenesis in endothelial cells.

2015

10 páginas, 5 figuras

0301 basic medicineVascular Endothelial Growth Factor AAngiogenesisretinal pigment epitheliumNeovascularization PhysiologicexosomesBiologyExosomesExosomeCell Line03 medical and health sciencesangiogenesismedicineHuman Umbilical Vein Endothelial CellsHumansRNA MessengerRetinal pigment epitheliumVEGF receptorsTube formationRetinal pigment epitheliumEthanolCell BiologyOriginal ArticlesMicrovesicleseye diseasesCell biologyEndothelial stem cellVascular endothelial growth factor AOxidative Stress030104 developmental biologymedicine.anatomical_structureReceptors Vascular Endothelial Growth FactorOxidative stressCell cultureMolecular MedicineOriginal ArticleAngiogenesissense organsJournal of cellular and molecular medicine
researchProduct

Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells

2016

We examined the effects of the histone deacetylase inhibitor (HDACi) suberoylanilide\ud hydroxamic acid (SAHA) combined with the vascular endothelial growth factor receptor-1/2 inhibitor\ud (3Z)-5-hydroxy-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-2-one on MDA-MB-231 breast\ud cancer cells (triple-negative) in the form of both a cocktail of the separate compounds and a chemically\ud synthesized hybrid (N-hydroxy-N'-[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol-\ud 5-yl]octanediamide). Comparative flow cytometric and Western blot analyses were performed on\ud cocktail- and hybrid-treated cells to evaluate cell cycle distribution, autophagy/apoptosis modulation,\ud an…

0301 basic medicineVascular Endothelial Growth Factor AIndolesCytotoxicityTriple Negative Breast Neoplasmsbreast cancer; MDA-MB231 cells; histone deacetylase inhibitor; vascular endothelial growth factor receptor-2 inhibitor; cytotoxicity; cell cycle; apoptosis; autophagy; mitochondrial metabolismHydroxamic AcidsCatalysi0302 clinical medicineBreast cancerTumor Cells CulturedCytotoxic T cellSettore BIO/06 - Anatomia Comparata E CitologiaSpectroscopyVorinostatVascular endothelial growth factor receptor-2 inhibitorApoptosis; Autophagy; Breast cancer; Cell cycle; Cytotoxicity; Histone deacetylase inhibitor; MDA-MB231 cells; Mitochondrial metabolism; Vascular endothelial growth factor receptor-2 inhibitor; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryKinaseHistone deacetylase inhibitorapoptosisComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineCell cycleFlow CytometryComputer Science ApplicationsCell biologyMDA-MB231 cell030220 oncology & carcinogenesisFemaleQD0241Programmed cell deathmedicine.drug_classCell SurvivalBlotting WesternAntineoplastic AgentsBiologyCell cycleCatalysisArticleInorganic Chemistry03 medical and health sciencesmedicineAutophagyHumansPhysical and Theoretical ChemistryProtein Kinase InhibitorsMolecular BiologyQD0415Histone deacetylase inhibitorAutophagyOrganic ChemistryApoptosiHistone Deacetylase Inhibitors030104 developmental biologyApoptosisMitochondrial metabolismMDA-MB231 cellsHistone deacetylaseInternational Journal of Molecular Sciences; Volume 17; Issue 8; Pages: 1235
researchProduct

Plasma leptin and vascular endothelial growth factor (VEGF) in normal subjects at high altitude (5050 m)

2013

Context: High altitude (HA) is a model of severe hypoxia exposure in humans. We hypothesized that nocturnal hypoxemia or acute maximal exercise at HA might affect plasma leptin and VEGF levels. Objectives: Plasma leptin, VEGF and other metabolic variables were studied after nocturnal pulse oximetry and after maximal exercise in healthy lowlanders on the 3rd-4th day of stay in Lobuche (5050 m, HA) and after return to sea level (SL). Results: Leptin was similar at SL or HA in both pre- and post-exercise conditions. Pre-exercise VEGF at HA was lower, and cortisol was higher, than at SL, suggesting that nocturnal intermittent hypoxia associated with periodic breathing at HA might affect these v…

AdultLeptinMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyperiodic breathingPhysiologySettore MED/10 - Malattie Dell'Apparato RespiratorioBiologyNocturnalSettore BIO/09 - FisiologiaNOHypoxemiachemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumanssleepExercisemaximal exercise testhypoxiaAltitudeHypoxia maximal exercise test metabolism periodic breathing sleepLeptinHypoxia; Maximal exercise test; Metabolism; Periodic breathing; Sleep; Adult; Exercise; Female; Humans; Hypoxia; Leptin; Male; Oxyhemoglobins; Vascular Endothelial Growth Factor A; Altitude; Healthy Volunteers; Physiology; Physiology (medical)hypoxia; maximal exercise test; sleep; periodic breathing; metabolismIntermittent hypoxiaGeneral MedicineHypoxia (medical)Effects of high altitude on humansHealthy VolunteersVascular endothelial growth factorEndocrinologychemistryOxyhemoglobinsPeriodic breathingFemalemedicine.symptommetabolismArchives of Physiology and Biochemistry
researchProduct

Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicente…

2006

This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as third- or fourth-line therapy in a retrospective series of patients with metastatic colorectal cancer refractory to oxaliplatin and irinotecan. Patients and Methods: Most patients (90%) had been previously treated with adjuvant 5-fluorouracil/leucovorin, and all had received oxaliplatin-based regimens before receiving irinotecan- based second-line treatment. Sixty patients with irinotecan-refractory colorectal cancer received a regimen comprising weekly irinotecan 120 mg/m 2 as a 1-hour intravenous infusion and cetuximab 400 mg/m 2 infused over 2 hours as the initial dose and 250 mg/m 2 infus…

AdultMaleOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSettore MED/06 - Oncologia MedicaColorectal cancermedicine.medical_treatmentCetuximabAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisSurvival analysisAgedAged 80 and overChemotherapyCetuximabPerformance statusbusiness.industryGastroenterologyAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinErbB ReceptorsIrinotecanSettore MED/18 - Chirurgia GeneraleRegimenOncologyCamptothecinFemaleEpidermal growth factor receptor Oxaliplatin Vascular endothelial growth factorColorectal Neoplasmsbusinessmedicine.drugClinical Colorectal Cancer
researchProduct

Vascular endothelial growth factor expression in nasal polyps of aspirin-intolerant patients.

2012

Objective To study differences between aspirin-tolerant patients and aspirin-intolerant patients concerning vascular endothelial growth factor (VEGF) expression. Recent publications strongly suggest the involvement of VEGF and its receptors in the pathophysiologic process of nasal polyps. Design We subjected 43 polyp specimens to semiquantitative immunohistochemical analysis. We quantified VEGF and its receptors (Flk, Flt, and neuropilin) in all samples. To gain insight into potential VEGF-mediated cellular responses, we determined proliferative (Ki67) and apoptotic (caspase 3) indices. Patients Polyp samples were obtained from 22 aspirin-intolerant patients and from 21 aspirin-tolerant pat…

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAdolescentApoptosisStatistics Nonparametricchemistry.chemical_compoundNasal Polypsotorhinolaryngologic diseasesNeuropilinMedicineHumansNasal polypsReceptorAspirinAspirinbusiness.industryCaspase 3General MedicineMiddle Agedmedicine.diseaseImmunohistochemistryPathophysiologyVascular endothelial growth factorVascular endothelial growth factor AKi-67 AntigenReceptors Vascular Endothelial Growth FactorOtorhinolaryngologychemistryImmunohistochemistrySurgeryFemalebusinessmedicine.drugArchives of otolaryngology--headneck surgery
researchProduct

The VEGF/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence

2012

<b><i>Background/Aims:</i></b> The molecular mechanisms downstream of mutated neurofibromatosis type 2 (NF2) gene resulting in the growth and development of vestibular schwannoma (VS) are controversial. Several lines of evidence suggest the involvement of the vascular endothelial growth factor (VEGF) pathway in VS development. Given that recent studies of VEGF blockade in patients with NF2-associated VS showed positive effects on VS growth control, we initiated this comprehensive study of the VEGF pathway in sporadic VS. <b><i>Methods:</i></b> A tissue microarray analysis of 182 sporadic VS was conducted. The expression of VEGF and its recepto…

AdultMaleVascular Endothelial Growth Factor APathologymedicine.medical_specialtyAdolescentYoung Adultchemistry.chemical_compoundNeuropilin 1medicineHumansNeurofibromatosis type 2ReceptorAgedCell ProliferationCell growthbusiness.industryNeuroma AcousticMiddle Agedmedicine.diseaseNeuromaImmunohistochemistryVascular Endothelial Growth Factor Receptor-2Neuropilin-1BlockadeVascular endothelial growth factorReceptors Vascular Endothelial Growth FactorOtorhinolaryngologychemistryTissue Array AnalysisImmunohistochemistryFemaleNeoplasm Recurrence LocalbusinessORL
researchProduct

Relaxin in Obstructive Sleep Apnea: Relationship with Blood Pressure and Inflammatory Mediators

2015

<b><i>Background:</i></b> Obstructive sleep apnea (OSA) is associated with nocturnal intermittent hypoxia, which may be responsible for increased circulating levels of vascular endothelial growth factor (VEGF) and inflammatory mediators, such as metalloproteinases (MMPs), and which contributes to the pathogenesis of systemic hypertension. Why some OSA patients remain normotensive is poorly understood. Relaxin-2, a pregnancy hormone, may sometimes circulate in men and could increase in hypoxic conditions. It exerts a vasodilatory activity and can modulate the release of molecules, such as MMPs and VEGF. <b><i>Objectives:</i></b> The objective o…

AdultMaleVascular Endothelial Growth Factor APulmonary and Respiratory Medicinemedicine.medical_specialtyAmbulatory blood pressurePolysomnographyBlood PressurePolysomnographySettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRelaxin · Obstructive sleep apnea · Metalloproteinase · Vascular endothelial growth factorInterquartile rangeInternal medicineRespiratory disturbance indexmedicineHumansHypoxiaInflammationSleep Apnea ObstructiveTissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-1medicine.diagnostic_testbusiness.industryRelaxinSleep apneaTissue Inhibitor of MetalloproteinasesIntermittent hypoxiaMiddle Agedmedicine.diseaseMatrix MetalloproteinasesObstructive sleep apneaEndocrinologyBlood pressureMatrix Metalloproteinase 9030228 respiratory systemHypertensionMatrix Metalloproteinase 2Inflammation MediatorsbusinessRespiration
researchProduct

Vascular endothelial growth factor gene polymorphisms in Behçet's disease

2004

Objective. To evaluate potential associations of vascular endothelial growth factor (VEGF) gene polymorphisms with Behçet's disease (BD) and disease expression. Methods. Case patients were 122 consecutive Italian patients with BD followed at the Rheumatology, Ophthalmology, and Neurology Units in Bologna, Ferrara, Milano, Palermo, Potenza, Prato, Reggio Emilia, and Trento over a 3-year period (1997-99) and who satisfied the International Study Group criteria for BD. Also selected as a control group were 200 healthy age and sex matched blood donors. All patients with BD and controls were genotyped by polymerase chain reaction and allele-specific oligonucleotide techniques for +936 C/T (rs302…

AdultMaleVascular Endothelial Growth Factor Aclinical manifestationsPolymorphism GeneticAdolescentGenotypeBehcet SyndromeVEGF productionBehcet's diseaseVEGF polymorphismGene FrequencyLeukocytes MononuclearHumansAdolescent; Adult; Behcet Syndrome; Cells Cultured; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Leukocytes Mononuclear; Male; Vascular Endothelial Growth Factor A; Polymorphism GeneticFemaleGenetic Predisposition to DiseaseCells Cultured
researchProduct